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REVIEW
Stem cell-derived exosomes: roles 
in stromal remodeling, tumor progression, 
and cancer immunotherapy
Farah Fatima1,2 and Muhammad Nawaz1,2* 
Abstract 
Stem cells are known to maintain stemness at least in part through secreted factors that promote stem-like pheno-
types in resident cells. Accumulating evidence has clarified that stem cells release nano-vesicles, known as exosomes, 
which may serve as mediators of cell-to-cell communication and may potentially transmit stem cell phenotypes to 
recipient cells, facilitating stem cell maintenance, differentiation, self-renewal, and repair. It has become apparent that 
stem cell-derived exosomes mediate interactions among stromal elements, promote genetic instability in recipi-
ent cells, and induce malignant transformation. This review will therefore discuss the potential of stem cell-derived 
exosomes in the context of stromal remodeling and their ability to generate cancer-initiating cells in a tumor niche 
by inducing morphologic and functional differentiation of fibroblasts into tumor-initiating fibroblasts. In addition, the 
immunosuppressive potential of stem cell-derived exosomes in cancer immunotherapy and their prospective appli-
cations in cell-free therapies in future translational medicine is discussed.
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Introduction
Cancer stem cells (CSCs) are tumor cells with substan-
tial potential for self-renewal, clonal tumor initiation, 
long-term repopulation, and phenotypic plasticity pres-
ervation [1, 2]. A number of cell surface markers, such 
as CD34, CD133, CD24, CD44, CD166, and epithelial 
cell adhesion molecule (EpCAM), are used to identify 
and enrich CSCs from several types of cancer [3–6]. 
Although the origin of CSCs and the prediction of their 
biological activity are controversial subjects, they have 
been explained using a CSC model (also known as a hier-
archical model). This model posits that a defined sub-
set of biologically distinct cells is solely responsible for 
initiating malignancy [7, 8] and that the tumor popula-
tion is hierarchically arranged within the tumor niche 
[9]. Subsequently, the tumor-initiating activity can be 
enriched by sorting cells on the basis of intrinsic char-
acteristics and may be prospectively isolated based on a 
specific cell surface phenotype [7].
In contrast, the stochastic model of cancer posits that 
all of the cells within a cancer have equal potential to act 
as cancer-initiating cells (CICs) that propagate the cancer 
[10–12]. Tumor-initiating activity cannot be improved by 
sorting cells based on intrinsic characteristics and cannot 
be prospectively determined based on the environment 
in which the cells reside. This model assumes that the 
activities of CICs are governed by re-entry into the cell 
cycle, which is in fact a low-probability stochastic event, 
making it impractical to realistically identify the tumor-
initiating subset.
The last decade has witnessed remarkable progress 
in stem cell-based therapies with promising clini-
cal applications (reviewed in [13]). Recent trends in 
translational medicine are reliant on the application 
of stem cells, largely because of stem cells’ potential in 
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tissue regeneration and defect repair. The potential use 
of stem cells for both cellular and non-cellular therapies 
could offer a promising opportunity to treat tumors and 
immune diseases for which existing therapeutic strate-
gies pose potential challenges.
Of prime importance are mesenchymal stem cells 
(MSCs), which represent a heterogeneous pluripotent 
population of plastic-adherent cells that exhibit a fibro-
blast-like morphology and form distinct colonies when 
seeded at clonal densities [14]. MSCs are commonly 
derived from bone marrow (BM), adipose tissue, nerv-
ous tissue, amniotic fluid, the umbilical cord, the pla-
centa, menstrual blood, and even dental pulp [15], with 
differences in morphology, differentiation, proliferation 
and self-renewal ability, and multilineage differentiation 
potential [16]. Remarkably, the differentiation capac-
ity of MSCs may have potential clinical implications for 
the treatment of various diseases, as these cells could be 
activated and recruited to sites of tissue damage, where 
they could induce regenerative programs for repairing 
defects. Although these cells’ differentiation potential is 
less than that of embryonic stem (ES) cells and induced 
pluripotent stem (iPS) cells, MSCs hold greater potential 
for clinical applications. Intriguingly, the most prominent 
therapeutic effect of MSCs is based on their immunoreg-
ulatory functions [15].
The biological effects and immunoregulatory functions 
of MSCs depend largely on secreted factors that poten-
tially stimulate tissue-intrinsic progenitor cell programs 
and may promote the differentiation and tissue-reparative 
properties of MSCs [15, 17]. Importantly, the secreted 
factors are critical in mediating crosstalk between the 
elements of the local stroma and stem cells, whereby the 
cells may assertively orchestrate themselves in a given 
tumor niche and may exchange cytoplasmic and genetic 
material. The fusion and exchange of biological mate-
rial are vital to cancer development and could therefore 
exhibit several features of CSCs [18]. In this regard, the 
exchange of oncogenic material, including stem cell sig-
natures, through secretory vesicles (exosomes) from stem 
cell hierarchies could represent several features of the 
originating cells. Therefore, we speculate that exosomes 
released from CSCs may reflect CSC features and that 
the morphologic and functional relevance of exosomes 
solely specific to CICs may potentially contribute to 
resolving the ambiguities in cancer-initiating activities 
and enrichment, which are hotly debated issues in the 
stochastic cancer model and the CSC model. However, 
further studies will be needed to link exosomes and the 
two cancer-initiating models to explain exosome-based 
cancer-initiating activities and enrichment.
Exosomes are nano-sized (40–200  nm) vesicles 
secreted by many types of cells and can be detected in 
various body fluids [19, 20]. The isolation and purification 
of exosomes can be achieved through a variety of con-
ventional and high-throughput technologies, depending 
largely on the source of exosomes and the relative choice 
of downstream analysis (reviewed comprehensively in 
[20]). Exosomes carry enormous populations of bioac-
tive molecules, such as mRNAs, microRNAs (miRNAs), 
and long non-coding RNAs (lncRNAs) [21–24]; genomic 
DNA, cDNA, and mitochondrial DNA (mtDNA) [25–
31]; and proteins and lipids [32–36]. Exosomes may 
transfer unique patterns of their contents to neighbor-
ing cells and may therefore induce the phenotypic modi-
fications in recipient cells, subsequently modulating the 
microenvironment [37, 38]. Interestingly, the molecular 
signatures of exosomes are specific to each tissue type, 
which makes exosomes ideal for clinical applications [20].
Accumulating data have clarified that exosomes may 
play vital roles in the pathophysiology of various diseases 
[39–48], with well-known effects on the development and 
progression of cancer [20, 49, 50]. Most often, exosomes 
promote cancer by suppressing immune surveillance 
mechanisms and fostering the development of drug 
resistance [51, 52], thus offering potential clinical applica-
tions in tumor targeting and vaccine development. Strik-
ingly, immunosuppressive exosomes of tumor origin can 
maintain tumor growth through stromal remodeling, pro-
angiogenic growth factor expression, intercellular genetic 
exchange, and chemoresistance [53]. Therefore, exosomes 
secreted by immunoreactive stem cells may represent a 
versatile resource for future cancer immunotherapy.
Biogenesis of exosomes
The biogenesis of exosomes follows the endocytic-exo-
cytic pathway, which involves various cellular compart-
ments, such as early and late endosomes, lysosomes, 
and multivesicular bodies (MVBs). The precise mecha-
nisms of biogenesis are not fully understood, but it is well 
known that sorting of exosomal cargo is a tightly regu-
lated process that occurs under the influence of differ-
ent sorting machineries (for the detailed mechanisms, 
see [20]). Once exosomes are sorted, they are released 
outside the cell following the fusion of MVBs with the 
plasma membrane.
The formation and secretion of exosomes by biologi-
cally active cells are arguably context-dependent, i.e., aris-
ing in response to repair processes or tumor progression. 
MSC-derived exosomes are originated from endocytosed 
lipid-raft microdomains [54], whereas the endocytic-
exocytic pathway may play a role in stem cell differentia-
tion through the release of membrane vesicles containing 
stem cell markers, such as prominin-1/CD133 [55]. Upon 
their release from stem cells, secreted exosomes partici-
pate in the maintenance of stem cell hierarchies (Fig. 1). 
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Notably, the knowledge about the mechanisms of the 
biogenesis and origin of exosomes from stem cells could 
enhance our understanding of exosomes’ functional rel-
evance and could aid in the development of strategies 
for engineering exosomes for prospective therapeutic 
applications.
Role of stem cell‑derived exosomes in maintaining 
stemness and regeneration
Secreted exosomes exhibit fundamental paracrine 
mechanisms that mediate cell-to-cell communication 
through direct receptor-mediated stimulation of target 
cells and the horizontal transfer of genetic material [22, 
38, 56]. It has been proposed that the exosome-mediated 
exchange of genetic information could be an integral ele-
ment of the continuum model of stem cell biology, in 
which the differentiation decision of stem cells is con-
ditioned by cell cycle transit and possibly by environ-
mental stimuli [57]. In this context, as paracrine factors, 
stem cell-derived exosomes might induce phenotypic 
changes in recipient cells through genetic exchange and 
might generate a functional link between stem cells and 
resident tissue under various physiologic and pathologic 
conditions.
Intriguingly, exosomal mRNA transcripts for pluri-
potent transcription factors such as Nanog, Oct-4, 
HoxB4, Rex-1, and the stem cell-specific Wnt-3 protein, 
all expressed in stem cell-derived exosomes, may repre-
sent several features of stemness, such as maintenance of 
self-renewal properties and expansion of progenitor cells 
[21]. Several studies have indicated that stem cell effec-
tors such as WNT [58, 59], Hedgehog [60], and β-catenin 
[61], which are expressed on stem cell-derived exosomes, 
may play a potential role in maintaining stemness (Fig. 1). 
Importantly, several other reports have clearly indicated 
that stem cell signatures expressed on exosomes play a 
vital role in maintaining stem cell characteristics, such as 
differentiation, self-renewal, and maturation [55, 62–65].
In fact, stem cell-derived exosomes may represent sev-
eral features of their cells of origin and may play a role in 
gain-of-function properties, genetic instability, and con-
sequent malignant transformation as well as the induc-
tion of reparative programs within injured tissues.
Induction of regenerative phenotypes
Exosomes released from MSCs are a newly discovered 
source of regeneration in injured tissues, participating 
in exosome-mediated transfer of regenerative molecules 
Fig. 1 Biogenesis of exosomes and their role in maintaining stemness: exosome formation follows the endocytic-exocytic pathway, which is initi-
ated upon receiving extrinsic or intrinsic signals in a context-dependent manner, i.e., in response to either a disease signal or a reparative signal 
related to tissue injury. The regions of plasma membrane enriched in lipid-raft microdomains (red bars) are inveginated, resulting in the formation of 
early endosomes and their maturation into late endosomes (steps 1–3), with a series of changes occurring under the influence of multicomponent 
sorting machinery [20]. Multivesicular bodies (MVBs) fuse with the plasma membrane and secrete exosomes outwardly; these exosomes may inter-
act with resident cells and may facilitate stemness, i.e., self-renewal, clonal expansion, differentiation, and repair. MSCs, mesenchymal stem cells
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to target cells in a paracrine fashion. For example, stem 
cell-derived exosomes participate in the suppression of 
inflammatory responses through the inhibition of hyper-
proliferative pathways, thus restoring bioenergetics to 
promote cell survival [66–69]. Moreover, these exosomes 
may have the potential to reduce infract size and ame-
liorate heart functions through promoting neovasculari-
zation [70–73]. MSC-derived exosomes appear to have 
multi-pluripotent effects on neurovascular plasticity in 
rats during traumatic brain injury by promoting endog-
enous angiogenesis and neurogenesis accompanied by 
reduced neuro-inflammation [74, 75]. The anti-inflam-
matory and protective effects of MSC-derived exosomes 
were also observed during sciatic nerve regeneration in 
rats that received peripheral nerve cell therapy [76].
Stem cell-derived exosomes may play a role in accel-
erating the morphologic and functional recovery of the 
liver through exosome-mediated horizontal transfer of 
specific mRNA subsets [77], activation of proliferative 
and regenerative responses [78], reduction in hepatic 
inflammation, and inhibition of the epithelial-mesenchy-
mal transition in the fibrotic liver [79]. Similarly, acute 
and chronic lung injuries may be recovered through the 
secretion of exosomes by MSCs, conferring stem cell-like 
phenotypes on injured cells to promote self-regenerative 
programs [80, 81]. Interestingly, the protective effects 
of MSC-derived exosomes are comparable to those of 
MSCs, as could be observed in renal recovery [82–85] 
and wound and bone healing [86–88], indicating that 
exosomes are functional extensions of MSCs.
Anti‑apoptotic effect of MSC‑derived exosomes 
and tissue regeneration
Exosomes released from MSCs may potentially stimulate 
cell survival by inducing anti-apoptotic effects in injured 
cells and by promoting cell proliferation, as has been well 
explained for cardiomyocytes [73, 89] and injured renal 
tubular epithelial cells [90–93]. In fact, exosomes transfer 
anti-apoptotic miRNAs from stem cells to injured tissues 
and may contribute to cell survival by transcriptionally 
repressing the expression of apoptotic genes and activat-
ing cell survival signaling. Exosomes released from MSCs 
and iPS cells could deliver cardioprotective miRNAs to 
cardiomyocytes in  vitro, thereby producing cytoprotec-
tive effects and subsequently ameliorating heart function 
[94, 95]. In addition, exosome-mediated transfer of miR-
NAs to cardiac progenitor cells may play a role in pro-
moting repair programs in the heart [96, 97].
Exosome-mediated transfer of miRNAs from MSCs 
promotes neural plasticity and functional recovery after 
treatment of stroke in the rat brain [98] and may also 
increase neuronal differentiation of neural progeni-
tor cells [99]. Anti-apoptotic effects of MSC-derived 
exosomes could also be observed during rat pheochro-
mocytoma protection through apoptotic regulation, 
i.e., through down-regulation of the expression of Bax, 
accompanied by reduced cleavage of caspase-3 and up-
regulation of Bcl-2 [100]. These findings imply that trans-
plantation of MSC-derived exosomes has enormous 
potential to protect against cerebral injury and possibly 
other neuronal diseases.
Role of stem cell‑derived exosomes in tumor 
progression and inhibition
Several lines of evidence indicate the prospective roles 
of MSCs and their secreted exosomes in initiating tumor 
phenotypes. For example, in human renal cell carcinoma, 
a subset of tumor-initiating cells expressing the MSC 
marker CD105 release exosomes that promote tumor 
growth [101, 102], probably through enhanced expres-
sion of genes associated with cell migration, matrix 
remodeling, and angiogenesis [102]. Exosomes from adi-
pose-derived MSCs (AT-MSCs) are enriched in distinct 
patterns of RNAs that may potentially induce adipogen-
esis, angiogenesis, apoptosis, and proteolysis in recipi-
ent cells [103]. Exosomes from gastric cancer-derived 
MSCs may deliver miRNAs to human gastric cancer cells 
and promote their proliferation and migration [104]. 
Recently, it was shown that glioma-associated stem cells 
produce substantial amounts of exosomes that exhibit 
glioma stem cell features and that are capable of sustain-
ing the malignant properties of both glioma cells and gli-
oma stem cells, mainly through the release of exosomes 
[105].
Moreover, exosomes from BM-derived MSCs (BM-
MSCs) transport tumor regulatory miRNAs, anti-apop-
totic proteins, and metabolites that promote breast 
tumor growth [106]. Exosomes from BM-MSCs express 
higher levels of oncogenic proteins, cytokines, and adhe-
sion molecules, which can be transferred to multiple 
myeloma cells, subsequently modulating tumor growth 
in vivo [107].
Lately, it has become apparent that stem cell-derived 
exosomes may contribute to tumor progression due 
to these exosomes’ ability to activate signaling path-
ways by expressing exosome-borne growth factors. For 
instance, exosomes from BM-MSCs appear to enhance 
the expression of vascular endothelial growth factor 
(VEGF) through the activation of the extracellular sig-
nal-regulated kinase 1/2 (ERK1/2) signaling pathway to 
promote tumor growth [108]. Exosomes from mast cells 
express and shuttle mast/stem cell growth factor recep-
tor Kit (KIT), a member of the tyrosine kinase fam-
ily of growth receptors which promotes tumor growth 
in recipient lung adenocarcinoma cells by activating 
the KIT-stem cell factor (SCF) signaling pathway [109]. 
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Given that the Wnt signaling pathway is central to stem 
cell biology [110, 111], exosomes expressing the stem cell 
marker prominin-1 may play a potential role in Wnt sign-
aling and pro-metastatic activity in melanoma cells [112]. 
Taken together, these observations indicate that stem 
cell-derived exosomes potentially express tumor-pro-
moting molecules, such as miRNAs, oncogenic proteins, 
growth factors, and adhesion molecules, that engage in 
pro-metastatic and pro-angiogenic activities by activat-
ing signaling pathways (Fig. 2).
Intriguingly, MSC-derived exosomes not only have 
pro-tumor potencies but also can exert negative effects 
on tumor growth, depending on the conditions, the 
tumor type, and the stage of development [113] as well as 
the expression of tumor suppressor molecules. For exam-
ple, exosomes from BM-MSCs act as negative regulators 
of the cell cycle and exert inhibitory effects on tumor 
growth [114]. Moreover, exosomes from BM-MSCs 
can transfer miRNAs from the BM and promote dor-
mancy in metastatic breast cancer [115]. Breast cancer 
growth can also be inhibited by MSC-derived exosomes 
through miRNA-mediated VEGF suppression [116]. 
Similarly, exosome-mediated delivery of selective miR-
NAs from human liver stem cells may inhibit hepatoma 
growth [117]. Katakowski et  al. [118] have shown that 
intra-tumoral injection of MSC-derived exosomes 
expressing miR-146 could effectively inhibit glioma xen-
ograft growth. MSC-derived exosomes are capable of 
incorporating and delivering paclitaxel, which can inhibit 
tumor growth [119], indicating that stem cell-derived 
exosomes possess the potential for drug delivery to can-
cer cells.
Exosome-mediated delivery of tumor suppressor 
miRNAs and targeting of growth-regulatory pathways, 
such as the Wnt and Hedgehog pathways, as well as 
angiogenic pathways, such as the VEGF and kinase 
pathways, could be novel strategies to monitor tumor 
growth (Fig.  3). For example, the potent signaling 
axis miR-140/SOX2/SOX9, which regulates differen-
tiation, stemness, and migration, could be targeted to 
obstruct tumor progression [120]. Similarly, exosomes 
from MSCs could be effective in inhibiting bladder 
tumor cell growth by down-regulating the phospho-
rylation of Akt kinase [121], whereas exosome-medi-
ated targeting of the VEGF pathway could offer a novel 
strategy to inhibit tumor growth by inhibiting angio-
genesis [116]. However, it remains an open technical 
challenge to monitor the complex stromal network and 
to target these pathways within the dynamic tumor 
microenvironment.
Fig. 2 Stem cell-derived exosomes and tumor progression: exosomes derived from stem cells or cancer cells express a variety of molecules, 
comprising oncogenic microRNAs (miRNAs) and proteins, growth factors, and adhesion molecules that exhibit pro-metastatic and pro-angiogenic 
activities through activating signaling pathways. VEGF vascular endothelial growth factor, PDGF platelet-derived growth factor, KIT mast/stem cell 
growth factor receptor, MMPs matrix metalloproteinases, ERK1/2 extracellular signal-regulated kinase 1/2, SCF stem cell factor
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Mechanisms
Establishment of pre‑metastatic niche
The principal properties of CSCs are maintained by 
niches that are anatomically distinct regions within the 
tumor microenvironment [122]. Intriguingly, the pre-
metastatic niche may play a role in dormancy, relapse, 
and the development of metastasis. It has been hypoth-
esized that exosomes may act as metastasomes, help-
ing to establish secondary lesions by transmission of 
the metastatic phenotypes to the target organ via an 
exosome-borne tumor RNA signature [123]. Given that 
the construction of a pre-metastatic niche is an essential 
early step for CICs to survive and evolve [124], it could 
be speculated that stem cells may contribute to the con-
struction of the tumor-initiating niche at least in part by 
secreting exosomes. This concept may be further sup-
ported by observations that the interactions between 
endothelial cells and CSCs induce phenotypic changes 
in MSCs and promote the formation of a lung pre-meta-
static niche through the release of exosomes [101].
Exosomes released from a subset of CICs could induce 
an angiogenic phenotype in endothelial cells and could 
promote the formation of a pre-metastatic niche [101, 
102]. In fact, angiogenesis is one of the underlying mech-
anisms that shapes the tumor niche and is propagated by 
pro-angiogenic growth factors such as VEGF and plate-
let-derived growth factor (PDGF) [125]. In this regard, 
stem cell-derived exosomes appear to exert their pro-
angiogenic effects by promoting enhanced expression of 
VEGF in tumor cells [108]. In response to hypoxia, MSCs 
release an elevated level of exosomes, which may pro-
mote endothelial cell growth in vitro [126] and thus may 
potentially induce angiogenesis [127]. Exosomes released 
from AT-MSCs interact with endothelial cells and may 
transport angiogenic factors and subsequently promote 
angiogenic activity in a tumor niche [128]. It has been 
shown that exosomes released from adipose stromal cells 
(ASCs) are responsible for ASC-induced angiogenesis, 
whereas PDGF triggers an angiogenic effect by stimulat-
ing ASCs to release more exosomes [129], which may play 
a role in shaping a permissive tumor microenvironment.
Exosome‑mediated crosstalk among stromal elements
The general involvement of exosomes in intercellular 
communication suggests that they may contribute to 
the exchange of biological information within stem cell 
hierarchies, and thus, cancer stem-like cells may trans-
mit signals to their stroma by secreting exosomes. The 
exosome-mediated dynamic crosstalk within stromal ele-
ments may mobilize and re-localize the oncogenic factors 
that may shape the tumor environment. This speculation 
is based on the fact that carcinogenesis involves the re-
localization of cancer-associated fibroblasts (CAFs) to 
the tumor site, sustaining metastasis [130].
Fig. 3 Stem cell-derived exosomes and tumor inhibition: exosomes express and deliver antitumor molecules that exhibit tumor suppressor activi-
ties in recipient cells and that potentially inhibit tumor growth by targeting angiogenic, growth-regulatory, and other signaling pathways
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Several studies have demonstrated that stromal cell-
derived exosomes can also interact with cancer cells and 
can exchange oncogenic signatures present in tumor-
associated stroma. For example, intercellular communica-
tion mediated by fibroblast-derived exosomes promotes 
cancer cell motility via autocrine Wnt-planar cell polarity 
(PCP) signaling to drive invasive activities [58]. Consider-
ing the mechanism of cell-to-cell communication, Wnt3a 
could be exported to neighboring cells via exosomes that 
may modulate population equilibrium in the tumor niche 
[131]. Such features are expected to be established very 
early during tumorigenesis, whereas the prolonged com-
munication could sustain and aggravate tumor growth. 
It may be anticipated that the tumor microenvironment 
may also host multipotent stem cells that, by themselves, 
are non-tumorigenic but can support the biological activ-
ity of CICs through the release of exosomes.
Exosome‑mediated fibroblastic differentiation
The process of CSC plasticity, in which cancer cells present 
the dynamic ability to switch from a non-CSC state to a 
CSC state, can be modulated by secreted factors and cel-
lular interactions within a tumor niche [132]. In this regard, 
exosome-mediated interactions as well as fibroblastic dif-
ferentiation can implement switching of fibroblastic pheno-
types into CAFs. In fact, tumor cell-derived exosomes may 
reshape the tumor niche through fibroblastic differentia-
tion of MSCs. This concept implies that through the release 
of exosomes, tumor cells can “educate” MSCs towards CIC 
phenotypes arising within the microenvironment [133].
In fact, exosomes from cancer cells are capable of induc-
ing ASCs to acquire the characteristics of tumor-support-
ing myofibroblasts [134] and may promote phenotypic 
differentiation of MSCs into CAFs [135]. Chowdhury 
et al. [136] have reported a consistent phenotypic switch 
that operates via prostate cancer-derived exosomes, which 
promote the differentiation of MSCs into pro-angiogenic 
and pro-invasive myofibroblasts. Similarly, prostate can-
cer-derived exosomes induce phenotypic transformation 
of ASCs in prostate cancer patients to promote prostate 
cancer-like neoplastic lesions [137]. Shimoda et  al. [138] 
have proposed that activated CAFs influence tumor pro-
gression through the secretion of metalloproteinase-
enriched exosomes that promote cell motility and activate 
RhoA and Notch signaling in cancer cells. Surprisingly, 
exosomes from CAFs play a role in tumor recurrence and 
chemoresistance through promoting the clonogenicity of 
CSCs, which are inherently resistant to cell death [139].
Potential of stem cell‑derived exosomes in cancer 
immunotherapy
Due largely to their immunogenicity, these tiny immu-
nosomes have emerged as potential vectors for 
cancer immunotherapy. Exploiting the immunogenicity 
of exosomes, they could be implemented in clinical set-
tings and in the development of vaccination [140–143]. 
In particular, exosomes of tumor origin could be engi-
neered to deliver a potent immunogen with an ability 
to induce effective immune responses in recipient cells 
[144], representing a novel type of tumor vaccine.
Although a large amount of data have shown the 
potential of exosomes in regulating immune mecha-
nisms [145–147], the clinical information about stem 
cell-derived immunoregulatory exosomes is limited. 
However, emerging evidence has shown that MSCs are 
remarkably capable of secreting immunologically active 
exosomes, which may serve as a potent platform for 
stem cell-based cancer immunotherapy. Initial studies 
have indicated that exosomes secreted by human breast 
tumor cells could inhibit the differentiation of human 
monocytes in vitro [148], suggesting that tumor-derived 
exosome-mediated stimulation of murine myeloid pre-
cursors and induction of interleukin (IL)-6 play a critical 
role in immune modulation and inhibition of differentia-
tion. These findings imply that stimulation of precursors 
by tumor-derived exosomes could open an opportunity 
to use exosomes in cancer immunotherapy.
A recent study showed that hematopoietic progeni-
tor cell antigen CD34-containing exosomes from acute 
myeloid leukemia (AML) blasts appear to be immuno-
reactive [149]. Surprisingly, upon co-incubation with 
natural killer (NK) cells, captured blast-derived exosomes 
efficiently down-regulate the expression of surface NK 
group 2, member D (NKG2D). This result indicates that 
blast-derived exosomes can retain the ability to mediate 
immune suppression. Moreover, immunocaptured blast-
derived exosomes might be useful biomarkers for AML 
during the course of immunotherapy as a measure of dis-
ease progression as well as of the response to therapy.
Regulation of cytokine expression and immune cells 
by stem cell-secreted exosomes may also play a role 
in modulating inflammatory responses. For example, 
MSC-derived exosomes could induce higher expression 
of anti-inflammatory IL-10 and tumor growth factor-β1 
(TGF-β1) transcripts and reduce the levels of pro-inflam-
matory IL-1B, IL-6, tumor necrotic factor α (TNFα), and 
IL-12P40 transcripts [150], suggesting the use of these 
exosomes in immunotherapies for inflammatory dis-
eases. MSC-derived exosomes exert inhibitory effects 
on the differentiation and activation of T cells, followed 
by reduced T cell proliferation and interferon-γ (IFN-γ) 
release, suggesting that MSC-derived exosomes are ther-
apeutic agents for the treatment of inflammation-related 
diseases [151]. Exosomes from MSCs are strictly immu-
nostimulatory in their biological activities, which can 
activate autoreactive B and T cells in non-obese diabetic 
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mice [152]. In fact, immunization with exosomes may 
promote the expansion of transferred diabetogenic T 
cells and accelerate the effector T-cell-mediated destruc-
tion of islets, suggesting that stem cell-derived exosomes 
are autoantigen carriers, serving as prospective adjuvant 
therapy [152].
In summary, the multipotential aspects of stem cell-
derived exosomes in maintaining stem cell features and 
regulation of immune programs in recipient tissues could 
be a future clinical consideration for disease monitoring 
(Fig. 4). Although augmenting data support the opinion 
that exosomes could be a promising therapeutic resource 
for the treatment of immune diseases [43, 153], trans-
lating this technology into stem cell-derived exosome-
mediated cancer immunotherapy that offers minimized 
toxic effects and safety risks will need further studies.
Concluding remarks and future perspective
Despite improvement both in the surgical procedures 
for organ transplantation and in cell-based thera-
pies over the last decade, current methods present 
potential complications (for example, an increased risk 
of infection, toxicity, and graft rejection). In this con-
text, exosomes may offer a nontoxic framework of pro-
tective molecules during transplantation, as they are 
capable of inducing endogenous regenerative programs 
in damaged tissues.
Compared with traditional stem cell therapies, exo-
some-based cell-free therapy may improve patients’ 
outcomes considerably, reducing the complications of 
cell-based therapy. However, steering traditional stem 
cell-based therapy toward exosome therapy will need fur-
ther studies. Intriguingly, the combination of exosome-
based therapies with existing traditional approaches 
could improve the therapeutic benefits. The intriguing 
advantages of stem cell-derived exosomes in therapy are 
largely due to exosomes’ ability to stimulate endogenous 
repair processes within the injured tissue and their effi-
cient regulation of immune tolerance. Therefore, the 
administration of exosomes for prospective therapeutic 
applications may help to minimize the potential safety 
risks associated with cellular therapy or transplantation 
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• Differentiation and maturation
• Progenitor cell expansion
• Self-renewal
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programs and repair 
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• Premetastatic niche  and neoplastic 
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• Induction of effective immune 
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inflammatory niches
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Fig. 4 Stem cell-derived exosomes, their role in maintenance of stemness and tumor propagation, and their clinical potential in immunotherapy 
and organ transplantation. ESCs embryonic stem cells, iPSCs induced pluripotent stem cells, CAFs cancer-associated fibroblasts, CSC cancer stem 
cells
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surgery, preventing graft rejection. Manipulating the 
expression of exosomal contents related to angio-
genesis, growth, proliferation, and self-renewal could 
potentially improve blood flow recovery, may maintain 
tissue growth, and thus could ultimately ameliorate organ 
function.
Strikingly, haploidentical MSC transplantation could 
efficiently postpone the rejection of mismatched skin 
grafts in patients with severe treatment-resistant acute 
graft-versus-host disease (GVHD) [154], whereas 
immunosuppressive exosomes could potentially pre-
vent graft rejection [155]. These findings raise the pos-
sibility that immunosuppressive exosomes from MSCs 
could be a promising therapeutic resource for organ 
transplantation, preventing graft rejection with great 
efficacy. An example could be seen when an infusion 
of MSC-derived exosomes significantly enhances sur-
vival and delays the rejection of an allogenic skin graft, 
as observed in mice, with a corresponding increase in 
regulatory T cells [150]. Thus, the application of MSC-
derived exosomes could be a novel therapeutic platform 
for future clinical consideration due to the fact that 
MSC-derived exosomes are well tolerated in patients 
during the treatment of GVHD [156]. Moreover, MSC-
derived exosome treatment could efficiently reduce 
the pro-inflammatory cytokine response in patients’ 
peripheral blood mononuclear cells in  vitro, and the 
clinical symptoms of GVHD could be improved signifi-
cantly shortly after the start of MSC-derived exosome 
therapy [156]. Importantly, the exosome contents before 
and after BM-MSC treatment may potentially modulate 
the immune response [157], suggesting that the exoso-
mal contents of MSC products will be a consideration 
when used in the clinic in the future.
Despite that stem cell-derived exosomes have been 
employed in clinical practice for tissue repair and organ 
transplantation, their application in treating cancers 
seems challenging. The poor survival of cancer patients, 
which is mainly associated with the late stages of cancer, 
a lack of early diagnosis, recurrence, and resistance to 
existing therapies, poses a potential challenge for improv-
ing the long-term survival of patients and reducing the 
risks of mortality. In this regard, exosomes could serve as 
a promising resource for early diagnosis, enabling timely 
monitoring of the disease [20], as well as for developing 
novel cancer therapies alternative to existing therapies 
[158]. Cancer immunotherapy principally relies on evok-
ing the host immune system to fight against cancer cells, 
whereas the immunosuppressive tumor microenviron-
ment is considered a major barrier to the effectiveness 
of cancer immunotherapies [159]. Given that exosomes 
play a vital role in central tolerance, efficiently stimulat-
ing the immune system and potentially reshaping the 
immunosuppressive microenvironment [160], this poten-
tial could be exploited for the use of stem cell-derived 
exosomes in cancer immunotherapy, serving as a potent 
resource of antitumor agents. It is even more likely that 
exosomes will also serve as a measure of disease progres-
sion as well as the response to therapy during the course 
of immunotherapy.
It is well appreciated that the human T-cell response 
can be modified using viral and non-viral vectors to 
promote the selective targeting of cancer cells by intro-
ducing exogenous T-cell receptors (TCRs) or chimeric 
antigen receptors (CARs) [161]. In this regard, using 
exosomes as vectors for introducing TCRs and/or CARs 
that specifically target cancer cells may raise the novel 
possibility of using exosomes for cancer immunother-
apy. However, to validate this possibility, further studies 
will be needed.
Because they are free of potential safety risks, are 
non-toxic, and do not differentiate into unrequired pop-
ulations, in contrast to CSCs, exosomes could be a prom-
ising platform for cancer therapies. Moreover, precise 
understanding of the involvement of exosomes in CSC 
biology and their prospective potential in the prediction 
and enrichment of cancer-initiating activities may pre-
sent novel opportunities for developing effective thera-
pies against cancer. Importantly, the use of exosomes, 
and particularly those derived from MSCs, do not raise 
potential ethical and legal issues, in contrast to other 
types of stem cells, and especially human embryonic 
stem cells (ESCs). Of particular note, the cost of exosome 
engineering and manipulation would be significantly less, 
which will be an important clinical consideration.
Despite the enormous potential of exosomes in future 
clinical settings, strategies will need to be developed for 
the precise and adoptive manipulation of exosomes for 
effective usage in local transplantation, systemic infu-
sion, and engineering of their clinical benefits for cancer 
therapy. Moreover, whether the dose-dependent effects 
of exosomes in cancer model experiments are promis-
ing must be determined because increasing the dose of 
exosomes may produce unwanted phenotypes and may 
limit the accessibility of their application to a smaller 
number of patients. A potential challenge in the field 
exists due largely to the limitations of standardizing the 
existing technologies for the isolation, characterization, 
and engineering of exosomes for their prospective ther-
apeutic use. Therefore, a combination of different high-
throughput approaches and precisely optimized methods 
could overcome the potential limitations related to exo-
somal detection, characterization, and manipulation [20], 
which may be implicated in biomarker development and 
possibly in the clinical use of stem cell-derived exosomes 
in future cancer therapies [162].
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